Agenus | AGEN - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.58B 316M 2026-03
Agenus USD 10.56M 13.04M 2025-12
Amgen USD 1.58B 354M 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Celldex Therapeutics USD 11.45M 3.61M 2026-03
CSL USD 1.23B 498M 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Gilead Sciences USD 1.45B 326M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
Glaxosmithkline GBP 2.12B 1.44B 2026-03
Incyte USD 328.1M 62.31M 2026-03
Intrexon USD 10.31M 41K 2024-06
J&J USD 6.03B 719M 2026-03
Jiangsu Hengrui CNY 2.81B 191.05M 2026-03
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
MacroGenics USD 9.71M 1.77M 2026-03
Merck EUR 1.52B 80M 2026-03
Merck USD 2.67B 180M 2026-03
Northwest Biotherapeutics USD 7.07M 1.06M 2025-09
Novartis USD 3.14B 296M 2026-03
Novavax USD 25.53M 1.34M 2025-12
Pfizer USD 2.92B 1.16B 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Veracyte USD 50.84M 7.53M 2026-03